Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2003

View Archived Issues

Monoclonal antibodies that inhibit collagen-bacteria binding and their therapeutic use

Novel PPAR agonists developed by GSK scientists

Roche team prepares novel p38 kinase inhibitors

Novartis presents new IOP-lowering agents in recent patent

Several series of glycogen phosphorylase inhibitors described by AstraZeneca

New PDE4 inhibitors for inflammation, allergy, etc., under study at Ono

Phase III trial initiated for Bio-E-Gel

Genzyme and Transkaryotic enter agreement for I2S for Hunter's syndrome

IDN-6556 evaluated in liver transplant patients in new phase II trial

ILX-651 enters new phase II study in melanoma

FDA accepts Vitrase NDA for filing

Phase II/III study evaluates NGX-4010 for HIV/AIDS-associated neuropathic pain

Novartis and Sankyo to codevelop and commercialize new GERD treatment

Approvable letter for insulin detemir

Dosing completed in TOP study of Preos

Proof-of-concept study of teduglutide for Crohn's disease

Vernalis formed from merger of Vernalis, British Biotech and RiboTargets

Nymox develops neurodegenerative disease drug candidate

PI-0824 evaluated in new phase I trial in patients with pemphigus vulgaris

Successful completion of phase I trial of Tbeta4

Teva seeks marketing approval for rasagiline in Canada

Dalbavancin compared to vancomycin in new phase III trial

TA-NIC enters second phase I trial

Garenoxacin as a promising option for community-acquired respiratory tract infections

Acceptable toxicity profile described for GEM-231 against refractory solid tumors

Increased tissue levels of resiniferatoxin in pig bladder wall after electrical stimulation

High discontinuation rate found with long-term anticholinergic therapy for OAB

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...